BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
See today's BioWorld
Home
» Presidio Gains Early Hepatitis C Program from XTL in $108M Deal
To read the full story,
subscribe
or
sign in
.
Presidio Gains Early Hepatitis C Program from XTL in $108M Deal
March 21, 2008
By
Jennifer Boggs
Small antiviral firm Presidio Pharmaceuticals Inc. picked up rights to a group of preclinical small molecules targeting hepatitis C virus in a potential $108 million deal with XTL Biopharmaceuticals Ltd. (BioWorld Today)
BioWorld
